– New data showcase safety profile of twice-yearly lenacapavir for PrEP with other medications and recruitment strategies for PURPOSE 5 –
– Five-year BICSTaR results offer insights into long-term treatment with Biktarvy®, helping inform the future of coordinated, person-centered HIV care –
– Latest results on novel long-acting combination regimens, including once-weekly and twice-yearly treatment options –
Read the full company press release here.
Source : Gilead Sciences, Inc.
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.